Form 4: NEOGENOMICS Director Neil Gunn Reports Significant Equity Transactions, Including RSU Vesting and New Option Grants

NEOGENOMICS Inc. Director Neil Gunn has filed a Form 4 detailing the vesting of restricted stock units and the acquisition of new stock options and restricted stock units, increasing his beneficial ownership in the company.

Summary

• On June 1, 2025, Neil Gunn, a Director of NEOGENOMICS INC, acquired 12,254 shares of common stock at a price of $0, resulting from the vesting and conversion of previously reported restricted stock units (RSUs).
• Following this transaction, Mr. Gunn's direct beneficial ownership of common stock increased to 28,100.31 shares.
• Concurrently, 12,254 restricted stock units were disposed of as they converted into common stock upon vesting.
• Mr. Gunn was granted 16,107 new stock options with an exercise price of $7.28, which become exercisable on June 1, 2026, and expire on June 1, 2035.
• Additionally, Mr. Gunn was granted 23,077 new restricted stock units at a price of $0, which will vest starting June 1, 2026.
• Mr. Gunn also holds previously reported stock options: 8,353 options with an exercise price of $14.82 (exercisable from August 10, 2024, expiring August 10, 2033) and 8,672 options with an exercise price of $13.71 (exercisable from June 1, 2025, expiring June 1, 2034).

Sentiment

Score: 5

Explanation: The document is a routine Form 4 filing detailing insider transactions related to compensation. It does not contain information that would significantly alter the perception of the company's financial health or strategic direction, thus indicating a neutral sentiment.

Positives

• The vesting of 12,254 restricted stock units at a $0 cost basis directly increased Neil Gunn's common stock holdings.
• The grant of 16,107 new stock options and 23,077 new restricted stock units indicates continued compensation and alignment of interests between the director and shareholders.

Future Outlook

This Form 4 filing does not contain any forward-looking statements or guidance regarding the company's future financial performance or strategic outlook.

Industry Context

This filing is a routine disclosure of insider equity transactions, common across all industries for publicly traded companies, reflecting compensation and ownership changes for a director. It does not provide specific insights into broader industry trends or competitive landscape.

Stakeholder Impact

• Shareholders: The report provides transparency regarding a director's equity holdings and compensation structure, which can be relevant for corporate governance analysis.
• Employees: The equity grants to a director may reflect the company's broader compensation philosophy, potentially influencing employee incentive programs.

Key Dates

Keywords

NEOGENOMICS INC, NEO, Form 4, Insider Transaction, Restricted Stock Units, Stock Options, Beneficial Ownership, Director Compensation, Equity Grant, Vesting